Helus Pharma Appoints Former Pfizer CMO as Advisory Chair in $40B Psychiatric Market
Helus Pharma named Dr. Freda Lewis-Hall, former Pfizer CMO, to its Board and as Scientific Advisory Chair for its novel serotonergic agonist programs. The move positions Helus to capture part of a global mental health therapeutics market projected beyond $40 billion by leveraging Lewis-Hall’s 40-year biopharma leadership.
1. Board Appointment of Dr. Freda Lewis-Hall
Helus Pharma named Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer, to its Board of Directors and appointed her Chair of its Scientific Advisory Committee. Dr. Lewis-Hall brings over 40 years of leadership in clinical care, global medical operations across 125 countries, and prior roles driving major drug approvals and a $3.4 billion spinout acquisition at SpringWorks Therapeutics.
2. Positioning in a $40B Psychiatric Market
Helus is developing novel serotonergic agonist therapies targeting depression, anxiety, PTSD and bipolar disorder in a market projected to exceed $40 billion. Lewis-Hall’s regulatory and commercialization expertise is expected to accelerate clinical milestones, strengthen FDA engagement and enhance Helus’s ability to capture market share as mental health treatment demand grows.